Sugi Predict

Sugi Predict / Compounds / SCHEMBL2552748

SCHEMBL2552748

SCHEMBL2552748

Cc1cc(=O)oc2cc(O)c(Cl)cc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MCL1 Q07820 4/20 1.00
▸ KDM4E B2RXH2 9/20 0.74
▸ ALDH1A1 P00352 7/20 0.74
▸ HPGD P15428 6/20 0.74
▸ HSD17B10 Q99714 6/20 0.74
▸ AKR1B1 P15121 2/20 0.74
▸ CYP3A4 P08684 1/20 0.74
▸ THRB P10828 1/20 0.74
▸ HTT P42858 1/20 0.62
▸ NCOA3 Q9Y6Q9 1/20 0.62
▸ GAA P10253 4/20 0.60
▸ GLA P06280 3/20 0.60
▸ GFER P55789 1/20 0.60
▸ CYP1A2 P05177 3/20 0.56
▸ CASP1 P29466 3/20 0.56
▸ CASP7 P55210 3/20 0.56
▸ LMNA P02545 2/20 0.56
▸ CA12 O43570 1/20 0.56
▸ CYP2C9 P11712 1/20 0.56
▸ UGT1A1 P22309 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31357189 1.00 MCL1 (1.00) MCL1KDM4EALDH1A1HPGDHSD17B10
4-Methylesculetin SCHEMBL409482 0.85 MCL1 (1.00) MCL1KDM4EALDH1A1HPGDHSD17B10
4-Methylesculetin SCHEMBL29361762 0.85 MCL1 (1.00) MCL1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL24865598 0.84 ALDH1A1 (0.82) MCL1KDM4EALDH1A1HPGDHSD17B10
4-Methylesculetin SCHEMBL6839210 0.84 MCL1 (0.96) MCL1KDM4EALDH1A1HPGDHSD17B10
4-Methylesculetin SCHEMBL27453331 0.84 ALDH1A1 (0.96) MCL1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL6904172 0.79 ALDH1A1 (0.74) MCL1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL22031603 0.79 ALDH1A1 (0.74) MCL1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL3075970 0.79 MCL1 (0.66) MCL1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL580501 0.79 ALDH1A1 (0.74) MCL1KDM4EALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2718458-B1 NOVEL METHOD FOR DETECTION OF BETA-D-GLUCURONIDASE BIOSYNTH AG (CH) 2015-07-08 — — EP claimed
US-20140212905-A1 Novel Method for Detection of Beta-D-Glucuronidase BIOSYNTH AG (CH) 2014-07-31 — — US claimed
EP-2532753-A1 Method for detection of beta-D-glucuronidase Biosynth AG (CH) 2012-12-12 — — EP claimed
CN-122079945-A Coumarin derivative containing substituted phenyl ether structure, preparation method and application thereof — 2026-05-26 — — CN disclosed
CN-119409871-A Acrylic acid metal salt resin containing coumarin structure, and preparation method and application thereof 中国海洋大学 2025-02-11 — — CN disclosed
CN-115430469-B Sliding micro-fluidic chip for rapidly detecting pathogenic bacteria 中国科学院上海微系统与信息技术研究所 2023-08-04 — — CN disclosed
WO-2023002349-A1 CHLORINATED 4'-ALKYLUMBELLIFERYL α-D-GLUCOPYRANOSIDE AND METHOD OF ASSESSING EFFICACY OF A STERILIZATION PROCESS INCLUDING THE SAME 3M INNOVATIVE PROPERTIES COMPANY (US) 2023-01-26 — — WO disclosed
CN-115430469-A Sliding micro-fluidic chip for rapid detection of pathogenic bacteria 中国科学院上海微系统与信息技术研究所 2022-12-06 — — CN disclosed
US-11337956-B2 IRE-1α inhibitors FOSUN ORINOVE PHARMATECH, INC. (CN) 2022-05-24 — — US disclosed
US-11337956-B2 IRE-1α inhibitors FOSUN ORINOVE PHARMATECH, INC. (CN) 2022-05-24 — — US disclosed
EP-3799870-A1 IRE-1A INHIBITORS Fosun Orinove Pharmatech, Inc. (CN) 2021-04-07 — — EP disclosed
US-20130116247-A1 IRE-1alpha INHIBITORS MANNKIND CORPORATION (US) 2013-05-09 — — US disclosed
WO-2012168415-A1 NOVEL METHOD FOR DETECTION OF BETA-D-GLUCURONIDASE BIOSYNTH AG (CH) 2012-12-13 — — WO disclosed
EP-2532753-A1 Method for detection of beta-D-glucuronidase Biosynth AG (CH) 2012-12-12 — — EP disclosed
WO-2011127070-A2 IRE-1α INHIBITORS MANNKIND CORPORATION (US) 2011-10-13 — — WO disclosed
WO-2007115181-A9 COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF EASTMAN CHEM CO (US) 2008-04-03 — — WO disclosed
US-20070254859-A1 Compounds exhibiting efflux inhibitor activity and composition and uses thereof EASTMAN CHEMICAL COMPANY 2007-11-01 — — US disclosed
WO-2007115181-A2 COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF EASTMAN CHEMICAL COMPANY (US) 2007-10-11 — — WO disclosed
US-5424320-A Antihistamine, antiallergic, antiinflammatory and cytoprotective agents MERCK FROSST CANADA, INC. (CA) 1995-06-13 — — US disclosed
US-5360815-A Heteroaryl cinnamic acids as inhibitors of leukotriene biosynthesis MERCK FROSST CANADA, INC. (CA) 1994-11-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254859-A1 Compounds exhibiting efflux inhibitor activity and composition and uses thereof ABCC4, NCOA4, NR4A3 MCL1 3353/4885KDM4E 1065/4885ALDH1A1 2000/4885
US-11337956-B2 IRE-1α inhibitors XBP1, ERN1, ERN2 MCL1 747/4885KDM4E 2619/4885ALDH1A1 1815/4885
US-20130116247-A1 IRE-1alpha INHIBITORS ERN1, XBP1, ERN2 MCL1 958/4885KDM4E 2975/4885ALDH1A1 2036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.